Trial Profile
ALONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia A
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Efmoroctocog alfa (Primary) ; Octocog alfa
- Indications Haemophilia A
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms A-LONG; ALONG
- Sponsors Biogen Idec; Bioverativ
- 31 Oct 2023 According to Octapharma media release, data from the study were presented in the European Journal of Haematology.
- 31 Oct 2023 Results of Indirect comparison from a matching-adjusted indirect comparison (MAIC) of Nuwiq (simoctocog alfa) versus extended half-life recombinant factor VIII (rFVIII) concentrates in haemophilia A patients undergoing personalised prophylaxis published in the Media Release
- 14 Jun 2023 According to Sanofi Media Release, the company will present new scientific data at ISTH 2023, the 31st Congress of the International Society on Thrombosis and Haemostasis.Nine abstracts have been accepted for presentation.